J W Valle

Summary

Affiliation: Christie Hospital
Country: UK

Publications

  1. pmc Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
    J W Valle
    Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 92:628-30. 2005
  2. pmc Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
    H Y Sheikh
    Department of Clinical Oncology, Christie Hospital, Manchester, UK
    Br J Cancer 99:577-83. 2008
  3. pmc Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study
    H Y Sheikh
    Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Br J Cancer 96:38-43. 2007
  4. doi request reprint A comparison of diagnostic imaging modalities for colorectal liver metastases
    L Bonanni
    Department of Hepatobiliary and Pancreatic Surgery, North Manchester General Hospital, Manchester, UK
    Eur J Surg Oncol 40:545-50. 2014
  5. ncbi request reprint A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
    A R Clamp
    Cancer Research UK and University of Manchester Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK
    Cancer Chemother Pharmacol 61:579-85. 2008
  6. ncbi request reprint Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume
    G C Jayson
    Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, United Kingdom
    J Clin Oncol 23:973-81. 2005
  7. ncbi request reprint Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib
    A LaMarca
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK
    Clin Transl Oncol . 2016
  8. doi request reprint Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery
    A E Slagter
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK University of Amsterdam, The Netherlands Electronic address
    Surg Oncol 25:223-8. 2016
  9. ncbi request reprint Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours
    V Clay
    Department of Medical Oncology, the Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK
    Clin Transl Oncol . 2016
  10. pmc Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    M P Saunders
    Department of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK
    Br J Cancer 91:1447-52. 2004

Collaborators

Detail Information

Publications19

  1. pmc Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
    J W Valle
    Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 92:628-30. 2005
    ..4 months, 1-year survival of 25% and median survival of 6.5 months...
  2. pmc Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
    H Y Sheikh
    Department of Clinical Oncology, Christie Hospital, Manchester, UK
    Br J Cancer 99:577-83. 2008
    ..In total, 67% of eligible patients received second-line therapy. UFT plus LV with alternating irinotecan and oxaliplatin is an efficacious first-line treatment for mCRC, with minimal neurotoxicity and hand-foot syndrome...
  3. pmc Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study
    H Y Sheikh
    Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Br J Cancer 96:38-43. 2007
    ..We recommend a dose of irinotecan 180 mg m(-2) on day 1, oxaliplatin 100 mg m(-2) on day 15 and UFT 250 mg m(-2) day(-1) with LV 90 mg day(-1) on days 1-21 of a 28-day cycle for future studies...
  4. doi request reprint A comparison of diagnostic imaging modalities for colorectal liver metastases
    L Bonanni
    Department of Hepatobiliary and Pancreatic Surgery, North Manchester General Hospital, Manchester, UK
    Eur J Surg Oncol 40:545-50. 2014
    ....
  5. ncbi request reprint A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
    A R Clamp
    Cancer Research UK and University of Manchester Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK
    Cancer Chemother Pharmacol 61:579-85. 2008
    ..This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma...
  6. ncbi request reprint Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume
    G C Jayson
    Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, United Kingdom
    J Clin Oncol 23:973-81. 2005
    ....
  7. ncbi request reprint Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib
    A LaMarca
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK
    Clin Transl Oncol . 2016
    ..Identification of patients with advanced HCC-deriving preferential benefit from sorafenib is desirable, and treatment-related adverse events are potential clinical biomarkers...
  8. doi request reprint Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery
    A E Slagter
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK University of Amsterdam, The Netherlands Electronic address
    Surg Oncol 25:223-8. 2016
    ..The aim of this study was to identify prognostic factors associated with disease relapse in patients with NETs treated by potentially-curative surgery...
  9. ncbi request reprint Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours
    V Clay
    Department of Medical Oncology, the Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK
    Clin Transl Oncol . 2016
    ..The aim of this study was to analyse the diagnostic and prognostic values of the Ki-67 index in PC...
  10. pmc Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    M P Saunders
    Department of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK
    Br J Cancer 91:1447-52. 2004
    ..It represents an effective treatment for patients who require close supervision and support, throughout their initial exposure to chemotherapy for this disease, and this dose combination was recommended for an ongoing phase II study...
  11. pmc Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
    J W Valle
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 101:621-7. 2009
    ..We assessed the activity of gemcitabine (G) and cisplatin/gemcitabine (C/G) in patients with locally advanced (LA) or metastatic (M) (advanced) biliary cancers (ABC) for whom there is no standard chemotherapy...
  12. doi request reprint Advances in the treatment of metastatic or unresectable biliary tract cancer
    J W Valle
    Christie Hospital The University of Manchester, Manchester, UK
    Ann Oncol 21:vii345-8. 2010
    ..g. EGFR, VEGF, MEK inhibition, amongst others) and collaboration between investigators to deliver relevant, timely and adequately powered studies...
  13. ncbi request reprint Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial)
    J W Valle
    Christie Hospital NHS Trust, Manchester, United Kingdom Imperial College Healthcare Trust, London, United Kingdom University of Birmingham, Birmingham, United Kingdom Royal Marsden Hospital, London, United Kingdom St James University Hospital, Leeds, United Kingdom Castle Hill Hospital, Hull, United Kingdom University College London, London, United Kingdom
    J Clin Oncol 27:4503. 2009
    ..gemcitabine (Gem) (Valle ASCO-GI 2006, abstr. 98). This study was extended into ABC-02, a phase III trial, to recruit a further 314 pts with overall survival (OS) as the primary end-point...
  14. doi request reprint Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
    J W Valle
    Manchester Academic Health Sciences Centre, the Christie NHS Foundation Trust, Manchester, UK
    Ann Oncol 25:391-8. 2014
    ..This pre-planned analysis evaluates the efficacy of CisGem with increased statistical power...
  15. pmc A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
    L Khoja
    Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 106:508-16. 2012
    ..We compared prospectively the utility of two platforms for CTC enumeration and characterisation in pancreatic cancer patients in a pilot exploratory study...
  16. ncbi request reprint Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting
    J W Valle
    Clin Oncol (R Coll Radiol) 17:666. 2005
  17. pmc Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma
    S Falk
    Bristol Haematology and Oncology Centre, Horfield Road, Bristol BS2 8ED, UK
    Br J Cancer 95:450-6. 2006
    ..Analysis of TS genotype, TS protein and expression did not reveal any correlation with outcome. OSI-7904L has activity in A-G/GEJA similar to other active agents and an acceptable safety profile...
  18. ncbi request reprint Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor
    M K Whitworth
    University Department of Reproductive and Developmental Medicine, Liverpool Women s Hospital, Crown St, L8 7SS, Liverpool, UK
    J Cancer Res Clin Oncol 132:41-4. 2006
    ..This study was designed to determine the relationship between intraperitoneal (IP) cytokine levels, and laparotomy in benign and malignant settings...
  19. pmc Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? National Institute of Clinical Excellence
    M P Saunders
    Br J Cancer 86:1667-9. 2002